CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

HYDROCHLOROTHIAZIDE; CANDESARTAN CILEXETIL

थमां उपलब्ध:

ALEMBIC PHARMACEUTICALS LIMITED

ए.टी.सी कोड:

C09DA06

INN (इंटरनेशनल नाम):

CANDERSARTAN AND DIURETICS

डोज़:

25MG; 32MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

HYDROCHLOROTHIAZIDE 25MG; CANDESARTAN CILEXETIL 32MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0244181003; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2014-06-11

उत्पाद विशेषताएं

                                ______________________________________________________________________________
_Candesartan Cilexetil and Hydrochlorothiazide Tablets Product
Monograph Page 1 of 50_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS
candesartan cilexetil and hydrochlorothiazide
tablets
Tablets, 16 mg / 12.5 mg, 32 mg / 12.5 mg and 32 mg / 25 mg, Oral use
House Standard
Angiotensin II AT
1
Receptor Blocker + Diuretic
CANADIAN IMPORTER AND DISTRIBUTOR:
Alembic Pharmaceuticals Canada Ltd.
225 Gibraltar Road, Unit 5
Vaughan, Ontario
L4H 4P9, Canada
MANUFACTURED BY:
Alembic Pharmaceuticals Limited
Alembic Road, Vadodara 390003,
Gujarat, India. Date of Initial Authorization:
June 11, 2014
Submission
Control Number: 259876 Date of Revision: July 22, 2022
______________________________________________________________________________
_Candesartan Cilexetil and Hydrochlorothiazide Tablets Product
Monograph Page 2 of 50_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions – Ophthalmologic
07/2022
7 Warnings and Precautions – Carcinogenesis and Mutagenesis
07/2022
7 Warnings and Precautions – Skin
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
RECENT MAJOR LABEL CHANGES
……………………………………………..……....2
TABLE OF
CONTENTS……………………………………………………………..……....2
PART I: HEALTH PROFESSIONAL INFORMATION
…………………
.
…………
..
…..
4
1
INDICATIONS…………………………………
.
……
.
….……………………..……....4
1.1
Pediatrics….…………………………………..….………………………………..4
1.2
Geriatrics….……………………………………...………………………………..4
2
CONTRAINDICATIONS
…………………………………………………………..…4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................. 
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 22-07-2022